Moreover, ATRA also targets the hallmark genetic abnormality in ARMS, inhibiting the PAX3-FOXO1 fusion protein’s expression and activity, thus disrupting oncogenic signaling and facilitating differentiation [49]. This evidence concerns the gene PAX3 and alveolar rhabdomyosarcoma.